Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication by Schuierer, Lukas et al.
RESEARCH Open Access
Impact of acyclovir use on survival of
patients with ventilator-associated
pneumonia and high load herpes simplex
virus replication
Lukas Schuierer1,2,3, Michael Gebhard4, Hans-Georg Ruf2, Ulrich Jaschinski5, Thomas M. Berghaus6,
Michael Wittmann7, Georg Braun8, Dirk H. Busch9 and Reinhard Hoffmann2,3*
Abstract
Background: Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high
proportion of ventilated intensive care unit (ICU) patients. However, the clinical significance remains poorly defined.
We investigated whether patients with ventilator-associated pneumonia not responding to antibiotics and in whom
high levels of HSV could be detected in respiratory secretions benefit from acyclovir treatment.
Methods: Respiratory secretions (bronchoalveolar lavage fluid or tracheal aspirates) were tested for HSV replication
by quantitative real-time PCR. ICU survival times, clinical parameters, and radiographic findings were retrospectively
compared between untreated and acyclovir treated patients with high (> 105 HSV copies/mL) and low (103–105
HSV copies/mL) viral load.
Results: Fifty-seven low and 69 high viral load patients were identified. Fewer patients with high viral load
responded to antibiotic treatment (12% compared to 40% of low load patients, p = 0.001). Acyclovir improved
median ICU survival (8 vs 22 days, p = 0.014) and was associated with a significantly reduced hazard ratio for ICU
death (HR = 0.31, 95% CI 0.11–0.92, p = 0.035) in high load patients only. Moreover, circulatory and pulmonary
oxygenation function of high load patients improved significantly over the course of acyclovir treatment: mean
norepinephrine doses decreased from 0.05 to 0.02 μg/kg body weight/min between days 0 and 6 of treatment
(p = 0.049), and median PaO2/FiO2 ratio increased from 187 to 241 between day 3 and day 7 of treatment (p = 0.02).
Chest radiographic findings also improved significantly (p < 0.001).
Conclusions: In patients with ventilator-associated pneumonia, antibiotic treatment failure, and high levels of HSV
replication, acyclovir treatment was associated with a significantly longer time to death in the ICU and improved
circulatory and pulmonary function. This suggests a causative role for HSV in this highly selected group of patients.
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Background
Latent herpes simples virus type 1 (HSV-1) and type 2
(HSV-2) infections are common in the human popula-
tion, with seroprevalence rates of 54% and 16%, respect-
ively [1]. Residing latently in sensory neurons, HSV
reactivates in states of reduced immunocompetence [2].
Several studies have shown that HSV-1 reactivation and
active replication in the respiratory tract are common in
mechanically ventilated intensive care unit (ICU) pa-
tients even without underlying immunosuppression, with
reported rates of 5 to 64% [3]. Ong et al., in the largest
study available to date, detected active HSV replication
in 27% of 393 ventilated ICU patients, which was associ-
ated with a nearly twofold increase in hospital mortality
(41% vs 24%, p = 0.002) [4].
Nevertheless, whether HSV replication in the lower re-
spiratory tract has clinical consequences remains contro-
versial [5, 6]. Linssen et al. reported that detection of more
than 105 HSV-DNA copies/mL in lower respiratory ma-
terial was associated with a significantly higher mortality
(41% vs 20%, p = 0.001) [7]. A recent meta-analysis dem-
onstrated a significant increase in mortality (odds ratio
1.8, 95% CI 1.2–2.6, p = 0.0001) for patients with HSV rep-
lication compared to patients without [8]. Whether this
increase in mortality is caused by HSV reactivation or
whether HSV reactivation is merely an indicator of a more
severe underlying disease remains unclear.
Similarly, cytomegalovirus (CMV) reactivation can be
detected in respiratory secretions of about 16% immuno-
competent ICU patients [9]. Much like in HSV, the clin-
ical consequences remain unclear.
Some case reports suggest that acyclovir treatment
may improve the clinical course of patients with detect-
able HSV reactivation [10–13]; however, this could not
be confirmed in larger studies [14–16]. To date, only
one study has suggested that acyclovir may reduce in-
hospital and ICU mortality, even after correcting for
confounders via propensity score matching [17]. The
reasons for these conflicting results remain unclear;
however, it is apparent that most of the previous studies
examined HSV replication, corresponding treatment,
and the impact on survival among a diverse range of
ICU patients. Often, stringent inclusion criteria for pre-
sumed viral ventilator-associated pneumonia (VAP) were
not employed, and patients were not stratified for viral
load. In fact, many patients with molecularly detectable
HSV replication may not have clinical signs of pneumo-
nia, precluding any conclusions regarding the thera-
peutic efficacy of acyclovir.
We observed that in some patients with high levels of
HSV replication in the lower respiratory tract, the clinical
status improved after initiation of antiviral treatment,
often allowing extubation several days later. Therefore, we
changed our treatment algorithm for patients with VAP
early in 2013. In patients with clinical signs of pneumonia
who did not respond to antibiotic treatment (as deter-
mined in joint rounds by clinicians and experienced clin-
ical microbiologists performed routinely three times per
week), HSV-1/2 testing of respiratory specimens was per-
formed. Antiviral treatment was strongly encouraged if
more than 105 HSV copies/mL could be detected. How-
ever, final treatment decisions were left to the responsible
physician. We hypothesized that these stringent selection
criteria would result in a significantly more homogeneous
patient population than in previous studies, with a higher
pretreatment likelihood of HSV pneumonia, and would,
for the first time, allow for direct evaluation of acyclovir
treatment efficacy in these patients.
Methods
Patient selection and PCR testing
We retrospectively identified all adult ICU patients who
were on ventilator support, received a diagnosis of VAP
and PCR testing on clinical grounds (as determined jointly
by clinicians and clinical microbiologists, based on ele-
vated C-reactive protein, leukocytosis, purulent tracheal
secretions, infiltrates on chest X-ray, or typical signs in
bronchoscopy), and had a viral load of > 103 HSV-1/2 cop-
ies/mL by PCR in respiratory specimens (excluding oro-
pharyngeal swabs from herpes-suspected lesions) within
the period of January 1, 2013, through April 1, 2018. We
defined the time point of VAP diagnosis as the first radio-
logical demonstration of pulmonary infiltrates. In those
patients without clear-cut infiltrates, a diagnosis of VAP
was made based on bronchoscopy findings. Neutropenic
patients (neutrophils < 1500/μL) were excluded. Response
to antibiotic treatment was assessed during regular daily
ICU rounds, usually 48 h after initiation; responding pa-
tients were excluded from the analysis. Quantitative HSV-
1/2 PCR was performed after automated DNA extraction
by COBAS AmpliPrep (Roche) with the RealStar HSV-
PCR kit 1.0 (AltonaDiagnostics) on a Rotor-Gene-Q ther-
mocycler (Qiagen) according to the manufacturer’s
recommendations. Additional CMV testing was per-
formed as required by the treating physician. Quantitative
CMV PCR was performed with the COBAS AmpliPrep/
COBAS TaqMan CMV test (Roche) according to the
manufacturer’s recommendations.
Clinical and radiographic scores
Day 0 (d0) was defined as the date of first detection of sig-
nificant HSV-1/2 replication (low load, 103–105 copies/
mL; high load, > 105 copies/mL) in untreated patients or
as the date of acyclovir treatment start for patients receiv-
ing acyclovir. Data were evaluated from d-4 up to d+14.
The Charlson Comorbidity Index was determined on
d0 based on the treating physician’s discharge letters
[18]. The “Acute Physiology, Age, Chronic Health
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Evaluation II” (APACHE II) score and “Sequential Organ
Failure Assessment” (SOFA) score were calculated on d0
and with the most abnormal values in first 24 h after
ICU admission, as described [19, 20]. The Glasgow
Coma Score was used as documented by responsible
ICU staff in the patient charts.
Chest X-rays and lung computed tomography (CT)
were taken based on individual clinical necessity as
assessed by treating ICU physicians. The standardized
Lung Injury Score (LIS) and the simplified version of the
Clinical Pulmonary Infection Score (CPIS) were calcu-
lated as described [21, 22]. Imaging results from all pa-
tients with a high viral load were re-analyzed in a
standardized way to quantitatively assess appearance and
distribution of pulmonary infiltrates over time. Based on
the descriptive radiologic part of the LIS score, we
assigned points to each of the six lung fields (upper/mid-
dle/lower, left, and right, respectively), with 1 point = “no
infiltrates,” 2 points = “discrete/questionable infiltrate,”
and 3 points = “distinct infiltrate.” We evaluated our
score by re-analyzing all radiographs using the descrip-
tive radiologic part of the LIS score with essentially iden-
tical results (Additional file 1: Figure S3).
Clinical and laboratory parameters
The clinical and laboratory parameters listed in Table 1
and Figs. 1, 2, 3, and 4 were extracted from the hospital
information systems (Hydmedia G5 and Orbis, Agfa),
from the laboratory information system (Swisslab, Nexus
AG, Donaueschingen, Germany), or manually from
handwritten ICU charts at different time points.
Norepinephrine use was recorded as micrograms/kilo-
gram body weight/minute. The following parameters
were calculated: partial pressure arterial oxygen and
fraction of inspired oxygen (PaO2/FiO2) ratio, alveolar-
arterial O2 gradient ([677 mmHg × FiO2 − (PaCO2/0.8)]
− PaO2), and lung compliance (tidal volume/[plateau
pressure − positive endexpiratory pressure]) [23, 24]. In
cases with more than one recorded value per day in the
chart, we used the 24-h arithmetic mean for analysis.
Statistical analysis
Statistical calculations were performed in R (version 3.5.0)
[25] with the following external packages: exactRankTests,
survival, survminer, ggplot2, and PMCMRplus [26–30].
The nonparametric Mann-Whitney U test and Fisher’s
exact test were used because data was not normally dis-
tributed. The Kaplan-Meier curves and the log-rank test
were used to analyze ICU survival. We then applied a
multivariable Cox regression model for the effect of
acyclovir on ICU survival time, adjusted for age, sex, and
SOFA score at d0. The Cox regression model was tested
for its proportional hazard assumption via the Schoenfeld
residuals tests. Additional models and a propensity score
analysis were calculated as shown in Additional file 1:
Table S2. The propensity score was determined in a logis-
tic regression model with acyclovir treatment as response
variable and age, sex, and SOFA score as predictor
covariates.
Daily medians of norepinephrine doses and PaO2/Fio2
ratios were analyzed for all patients without missing
values within 7 days from d0 using the nonparametric
Friedman test. This was followed by post hoc analysis by
the Friedman-Conover test with p value adjustment by
false discovery rate (fdr).
The radiographic score and the descriptive part of the
LIS score were analyzed by the Wilcoxon signed-rank test
comparing the last available X-ray or CT before d0 and
the maximum change within a time span of 3 to 15 days.
Results
Patient selection and baseline parameters
We tested respiratory secretions of 425 ICU patients for
HSV-1/2 replication by PCR. Of these, 126 (29.6%)
tested positive for at least 103 HSV-1 copies/mL. Only
one patient had additional HSV-2 replication (Fig. 1). All
but two patients had clinical signs of pneumonia (ele-
vated C-reactive protein, leukocytosis, purulent tracheal
secretions, pulmonary infiltrates, or typical signs in
bronchoscopy). Strikingly, 20/50 (40%) low viral load pa-
tients responded to culture-guided antibiotic treatment,
in contrast to 8/67 (12%) of high viral load patients (p <
0.001). These antibiotic responders as well as the two
patients without clinical signs of pneumonia were ex-
cluded from analysis, so that 89 patients with antibiotic
refractory VAP remained: 30 with low viral load (103–
105 copies/mL) and 59 with high viral load (> 105 cop-
ies/mL). Additional file 1: Table S1 shows microbiology
culture results and antibiotics received by these patients;
all were treated with at least one antibiotic active against
the bacteria identified. A significantly higher proportion
of high load patients received antiviral treatment (83% vs
57%, p = 0.005, Fig. 1).
The time from VAP diagnosis (detection of infiltrates)
to HSV detection was not significantly different between
untreated and acyclovir treated patients (Table 1), nor did
it correlate with viral load (Additional file 1: Figure S1).
In general, tracheobronchial secretions tended to have
higher HSV viral loads than bronchoalveolar lavages, al-
though this difference reached statistical significance
only in the entire cohort (p = 0.026, Additional file 1:
Figure S2a); it was not significant in the subgroups of
high and low load patients, respectively (Additional file 1:
Figure S2b, c).
As shown in Table 1, antiviral-treated patients had
higher HSV loads (median 1.1 × 106 vs 1.3 × 104, p <
0.001) especially in bronchoalveolar lavage fluid (median
1.1 × 106 vs 0.9 × 104, p < 0.001) and longer total ICU
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Table 1 Baseline clinical and treatment characteristics of the entire cohort and the subgroups (low/high viral load)
Variables All patients Low viral load (103–105 HSV
copies/mL)
High viral load (> 105 HSV copies/
mL)
Untreated
(n = 24)
Treated (n =
65)
p Untreated
(n = 14)
Treated
(n = 16)
p Untreated
(n = 10)
Treated (n =
49)
p
Age (years) 72 [67–76] 69 [59–76] 0.274 69 [61–77] 65 [46–75] 0.308 73 [71–76] 71 [60–76] 0.187
Female 12 (50) 23 (35) 0.230 9 (64) 4 (25) 0.063 3 (30) 19 (39) 0.729
Charlson score 4 [3–6] 4 [2–6] 0.281 4 [3–6] 3 [3–5] 0.179 4 [3–6] 4 [2–6] 0.743
Intubation (days) 9 [6–12] 13 [8–17] 0.017 9 [6–12] 12 [7–18] 0.324 10 [7–11] 14 [9–17] 0.109
Lung disease 15 (62) 31 (48) 0.241 9 (64) 10 (63) 1 6 (60) 21 (43) 0.488
COPD 12 (50) 13 (20) 0.008 7 (50) 2 (13) 0.046 5 (50) 11 (22) 0.116
Active smoker 6 (25) 18 (28) 1 4 (29) 5 (31) 1 2 (20) 13 (27) 1
Dialysis 7 (29) 19 (29) 1 5 (36) 7 (44) 0.722 2 (20) 12 (24) 1
Diabetes 6 (25) 13 (20) 0.771 4 (29) 3 (19) 0.675 2 (20) 10 (20) 1
Malignant diseases 3 (12) 10 (15) 1 2 (14) 2 (13) 1 1 (10) 8 (16) 1
Quantitative polymerase chain reaction results
BAL performed 18 (75) 45 (69) 0.793 12 (86) 13 (81) 1 6 (60) 32 (54) 0.733
HSV—copies/mL ×105 0.13 [0.05–
2.18]
10.78 [1.01–
60.15]
<
0.001
0.06 [0.04–
0.09]
0.16 [0.04–
0.40]
0.085 2.84 [1.80–
6.80]
30.69 [7.26–
12.42]
<
0.001
BAL: HSV—copies/mL ×105 0.09 [0.04–
1.22]
10.50 [0.41–
41.55]
<
0.001
0.05 [0.04–
0.09]
0.13 [0.03–
0.27]
0.205 2.37 [1.45–
2.89]
28.30 [6.77–
83.50]
0.005
TBS: HSV—copies/mL ×105 3.19 [0.61–
15.79]
19.29 [6.50–
143.9]
0.108 0.14 [0.10–
0.19]
0.55 [0.34–
0.76]
0.400 12.08 [3.92–
39.63]
44.85 [10.5–
169.2]
0.247
Pulmonary infiltrates
Infiltrates 16 (66) 54 (83) 0.143 11 (79) 13 (81) 1 5 (50) 41 (84) 0.033
Questionable but pathologic
brochoscopy
4 (17) 5 (8) 0.244 1 (7) 1 (6) 1 3 (30) 4 (8) 0.087
No infiltrates but pathologic
bronchoscopy
4 (17) 6 (9) 0.449 2 (14) 2 (13) 1 2 (20) 4 (8) 0.266
Days from detection of infiltrates to
HSV detection
7 [3–11] 8 [5–14] 0.318 6 [2–8] 8 [5–13] 0.126 12 [8–15] 8 [5–14] 0.444
Clinical score at day of HSV detection
APACHE II score 31 [25–37] 27 [22–33] 0.081 31 [25–37] 26 [21–34] 0.219 31 [28–36] 27 [22–33] 0.223
SOFA score 11 [7–13] 10 [6–11] 0.091 11 [8–14] 10 [6–11] 0.325 10 [8–13] 9 [6–11] 0.294
LIS score 2 [1.4–2.8] 2.3 [1.9–3] 0.050 2 [1.5–2.8] 2.2 [2.0–
3.0]
0.134 1.8 [1.1–2.6] 2.3 [1.8–3] 0.123
CPIS score 5 [3–6] 5 [3–6] 0.455 5 [4–5] 4 [3–5] 0.519 6 [3–7] 5 [3–6] 0.402
Antiviral treatment and relevant medication
Acyclovir – 63 (97) – – 14 (88) – – 49 (100) –
Ganciclovir – 3 (5) – – 2 (13) – – 1 (2) –
Hours from HSV detection to
treatment
– 46 [30–68] – – 48 [31–95] – – 44 [30–67] –
Acyclovir + antibiotics – 44 (68) – – 11 (69) – – 33 (67) –
Steroids at baseline 4 (17) 13 (20) 1 2 (14) 6 (38) 0.226 2 (20) 7 (14) 0.641
Antibiotic classes 4 [2–5] 5 [3–6] 0.025 4 [2–6] 6 [5–6] 0.051 4 [2.0–5] 5 [3–6] 0.124
Antibiotics (days) 15 [9–23] 18 [14–28] 0.046 20 [7–26] 26 [18–37] 0.094 12 [10–17] 17 [13–25] 0.045
Catecholamines 23 (96) 63 (97) 1 13 (93) 15 (94) 1 10 (100) 48 (98) 1
Catecholamines (days) 10 [5–13] 10 [7–19] 0.523 11 [4–12] 8 [6–20] 0.847 8 [6–14] 11 [8–18] 0.505
Diagnoses at ICU admission
Respiratory insufficiency 22 (92) 58 (89) 1 14 (100) 14 (88) 0.485 8 (80) 44 (90) 0.338
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and hospital stays (mean 26 vs 16 days, p = 0.009, and 41
vs 26 days, p = 0.004, respectively) than untreated pa-
tients. During the entire ICU stay, they had longer anti-
biotic treatment (18 vs 14.5 days, p = 0.046); had a
greater number of different antibiotic classes (5.0 vs 3.5,
p = 0.025), particularly ceftazidime (18% vs 0%, p =
0.031); and were intubated longer (13 vs 9 days, p =
0.017). On the other hand, treated patients had less
chronic obstructive pulmonary disease (20% vs 50%, p =
0.008) and required lower norepinephrine doses on d0
than untreated patients (median 0.001 vs 0.101 μg/kg
body weight/min, p = 0.009).
Among the subgroup with high viral load, those re-
ceiving antiviral treatment had higher HSV loads (me-
dian 3.1 × 106 vs 2.8 × 105, p < 0.001) and longer total
ICU and hospital stays (26 vs 15 days, p = 0.006, and 42
vs 24 days, p = 0.008, respectively) than untreated pa-
tients. They also received longer antibiotic courses (me-
dian 17 vs 12 days, p = 0.045) than untreated patients.
None of these differences were significant in the sub-
group with low viral load.
Survival time and Cox regression analysis
In the entire cohort of 89 patients with detectable re-
spiratory HSV replication, acyclovir had no significant
impact on ICU survival (Fig. 2a). Upon subgroup ana-
lysis, however, patients with high viral load who received
acyclovir had significantly longer median ICU survival
compared to patients without antiviral treatment (22 vs
8 days, p = 0.014; Fig. 2c), while no significant difference
was demonstrated in low viral load patients (Fig. 2b). To
correct for possible confounding, a multiple Cox regres-
sion model was adjusted for age, sex, and SOFA score
(Fig. 3). The Cox model key assumption of proportional
hazards was not violated as tested with the Schoenfeld
residuals tests. In all patient groups, higher SOFA scores
were consistently associated with increased hazard ratios
for ICU death (Fig. 3a–c). The impact of acyclovir on
survival remained significant only in high viral load pa-
tients (hazard ratio for ICU death 0.31, 95% CI 0.11–
0.92, p = 0.035; Fig. 3c). Additional Cox models adjusted
for different covariates (SOFA, APACHE II, COPD, HSV
viral load as continuous variable) and a propensity score ana-
lysis gave essentially identical results (see Additional file 1:
Table S2). Absolute ICU mortality, however, did not differ
between untreated and acyclovir treated patients in the entire
cohort (12/24 vs 26/65, p= 0.344), the low viral load sub-
group (6/14 vs 6/16, p= 1), or the high viral subgroup (6/10
vs 20/49, p= 0.311).
Impact of concomitant cytomegalovirus reactivation on
ICU survival
Overall, 66 of 89 patients were tested for CMV replica-
tion together with HSV. CMV replication could be de-
tected in 14/66 (21%) patients but had no effect on
median ICU survival (Additional file 1: Figure S4).
Table 1 Baseline clinical and treatment characteristics of the entire cohort and the subgroups (low/high viral load) (Continued)
Variables All patients Low viral load (103–105 HSV
copies/mL)
High viral load (> 105 HSV copies/
mL)
Untreated
(n = 24)
Treated (n =
65)
p Untreated
(n = 14)
Treated
(n = 16)
p Untreated
(n = 10)
Treated (n =
49)
p
Sepsis 14 (58) 26 (40) 0.153 9 (64) 9 (56) 0.722 5 (50) 17 (35) 0.477
Renal failure 9 (38) 15 (23) 0.188 7 (50) 2 (13) 0.046 2 (20) 13 (27) 1
Cardiac arrest 2 (8) 4 (6) 0.659 1 (7) 1 (6) 1 1 (10) 3 (6) 0.535
Reasons for mechanical ventilation
Sepsis 15 (63) 35 (54) 0.631 9 (64) 11 (69) 1 6 (60) 24 (49) 0.731
Heart failure 4 (17) 14 (22) 0.769 3 (21) 0 0.090 1 (10) 14 (29) 0.427
COPD exacerbation 6 (25) 7 (11) 0.104 3 (21) 2 (13) 0.642 3 (30) 5 (10) 0.126
Postoperative respiratory insufficiency 2 (8) 3 (5) 0.609 1 (7) 0 0.467 1 (10) 3 (6) 0.535
Intensive care unit stay and length of hospitalization
Surgical ICU 4 (17) 7 (11) 0.475 1 (7) 1 (6) 1 3 (30) 6 (12) 0.17
Medical ICU 20 (83) 58 (89) 0.475 13 (93) 15 (94) 1 7 (70) 43 (88) 0.17
Total days ICU 16 [10–28] 26 [17–32] 0.009 17 [6–31] 25 [16–32] 0.328 15 [12–17] 26 [17–32] 0.006
Death on ICU 12 (50) 25 (38) 0.344 6 (43) 6 (38) 1 6 (60) 20 (34) 0.311
Total days hospital 26 [17–38] 41 [26–56] 0.004 31 [19–43] 38 [26–51] 0.176 24 [16–34] 42 [26–56] 0.008
Death in hospital 13 (54) 30 (46) 0.634 7 (50) 7 (44) 1 6 (60) 23 (47) 0.506
The baseline data of the entire cohort and subgroups is listed in the corresponding column as median [interquartile range] or as absolute number (%). p values
were calculated using the Mann-Whitney U test for medians or Fisher’s exact test for categorical data comparing untreated to antivirally treated patients
(significant values are indicated in italics, < 0.05). Abbreviations: HSV herpes simplex virus, COPD chronic obstructive pulmonary disease, ICU intensive care unit, BAL
bronchoalveolar lavage fluid, TBS tracheobronchial secretions
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Changes in clinical and laboratory parameters over the
course of antiviral treatment
Upon antiviral treatment (Fig. 4), high viral load patients
improved in terms of circulatory support (from day 0 to
6 decrease in mean norepinephrine doses from 0.05 to
0.02 μg/kg body weight/min, fdr-adjusted p = 0.049;
Fig. 4a) and pulmonary oxygenation (median PaO2/FiO2
ratio increased during treatment from 187 on day 3 to
241 on day 7, fdr-adjusted p = 0.02; Fig. 4b). Pulmonary
and circulatory function of untreated patients remained
unchanged. Finally, we evaluated all chest X-rays and
CTs from high viral load patients. Scores of the first
radiograph were slightly worse in patients who subse-
quently received antiviral treatment than in patients who
did not (median 11 vs 8 points, p = 0.10; Fig. 4c), but
they improved significantly during the course of treat-
ment (11 vs 10 points, p < 0.001). The radiographic score
did not change in untreated patients for whom at least
two sequential X-rays were available for analysis.
Discussion
The role of HSV as a causative agent of VAP is subject of
active debate, since HSV replication is not infrequent in
ICU patients (29.6% in our cohort). Some studies have
shown that HSV replication is of clinical importance: Ong
et al. reported a prevalence of HSV viremia in 26% of sep-
tic shock patients admitted to the ICU [31] and Luyt et al.
published that 21% of prolonged ventilated patients with
clinical deterioration had histologically proven HSV
bronchopneumonitis [14]. Identification of these patients
under conditions of routine clinical care, however, is chal-
lenging, and a clinical algorithm would be helpful.
We suggest testing all patients with a diagnosis of VAP
who do not respond to antibiotics for HSV replication in
respiratory secretions. We adopted the suggested cutoff of
105 copies/mL [7], and several lines of evidence support
this: First, more patients with lower viral loads responded
to antibiotics than patients with higher viral loads, sug-
gesting the former may have mostly bacterial causes of
pneumonia. Second, the cutoff clearly separated patients
responding from those not responding to acyclovir, in
both uni- and multivariable analyses. This suggests that
high-grade HSV replication may be causative for VAP in
patients without other identifiable causes.
Our study is one of the few in which patients with a
high likelihood of viral VAP have been identified before
Fig. 1 Enrollment of patients with ventilator-associated pneumonia according to low or high viral load between 2013 and 2018: intensive care
unit (ICU) patients on ventilator support received a quantitative real-time polymerase chain reaction (PCR) testing of their respiratory material
(bronchoalveolar lavage or tracheobronchial aspirates) in context of a ventilator-associated pneumonia. Figure indicates numbers of patients;
figures next to outward pointing arrows show excluded patients. Reasons for exclusion are indicated in boxes. HSV-1, herpes simplex virus type 1;
HSV-2, herpes simplex virus type 2; AML, acute myelogenous leukemia; T-ALL, T cell acute lymphoblastic leukemia. *Statistically significant with
p < 0.05 by Fisher’s exact test
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testing for HSV replication. Luyt et al. prospectively ana-
lyzed 201 ICU patients who were ventilated for more
than 5 days, deteriorated clinically, and in whom active
lung disease was suspected [14]. These authors found
that the presence of histologic or cytologic signs of HSV
bronchopneumonitis was associated with higher HSV
viral loads. They could, however, not demonstrate any
effect of acyclovir treatment on clinical courses or
outcomes.
Several previous studies which examined the impact of
acyclovir treatment on survival analyzed ICU mortality
at one particular time point [14–16]. Since the risk of
non-HSV-associated, ICU-acquired complications in-
creases with the length of ICU stay, a survival benefit
caused by acyclovir may be underestimated by analyzing
mortality after a longer period of time. We found that
patients receiving acyclovir had significantly longer ICU
stays and a longer duration of mechanical ventilation
than untreated patients. We think that this is a conse-
quence of shorter ICU survival of untreated patients,
naturally resulting in a numerically reduced duration of
ICU stay or mechanical ventilation.
To date, only one study has demonstrated a similar
survival benefit of acyclovir, in 29 ICU patients with
positive HSV-1 by culture (PCR was not performed)
compared to 21 untreated patients (ICU mortality 21%
vs 48%, hospital mortality 28% vs 62%) [17]. Although
the patients receiving acyclovir treatment, like in our
study, had longer ICU stays (55 vs 31 days), and, there-
fore, had longer risk exposure to other ICU-related com-
plications, acyclovir treatment still was associated with
longer survival. This suggests that the impact of acyclo-
vir treatment on survival may be substantial if proper
patient selection was performed.
Since acyclovir was associated with a significant longer
time to ICU death in high load HSV patients, we ex-
pected that recovery of organ dysfunction should also
occur during the course of treatment. Indeed, circulatory
support, pulmonary oxygenation function, and radiologic
signs of pneumonia improved during treatment, but not
Fig. 2 a–c Kaplan-Meier analysis of intensive care unit survival after starting antiviral treatment or after HSV detection: day 0 (d0) was defined as
the date of first detection of significant HSV-1/2 replication in untreated patients or as the date of acyclovir treatment start for patients receiving.
+ = censored. The p values were calculated using a log-rank test. a Entire cohort. b Subgroup with low viral load (103–105 HSV copies/mL). c
Subgroup with high viral load (> 105 HSV copies/mL)
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in untreated patients. Since patients who quickly im-
proved upon antiviral treatment often did not have had
a second chest radiograph taken, we likely underesti-
mated radiographic improvement.
However, the following limitations should be consid-
ered: First, our study was retrospective and as such can-
not prove that acyclovir was causative for our patients’
improvement. However, we think that the effect of
acyclovir treatment on survival was surprisingly clear,
and the improvement in circulatory and pulmonary oxy-
genation function was quite impressive.
Second, the group of untreated high load patients is
quite small. This poses the question why these patients
have not been treated. It should be kept in mind that
this is a retrospective study of data acquired during
routine clinical practice, so the decision to provide or
withhold acyclovir treatment was left entirely to the re-
sponsible attending physician. In these patients, given
the lack of evidence at that time, detection of HSV repli-
cation in the respiratory tract was not considered clinic-
ally significant by our clinical staff. To minimize
selection bias, we determined a propensity score and
added it to a multivariable Cox regression model (as
shown in Additional file 1: Table S2), but the results
remained essentially the same.
Third, we cannot prove that HSV was the causative
pathogen leading to VAP in our patients since histopatho-
logic evaluation was not performed. However, we consider
it highly likely, because all patients in the final analysis
had signs of pneumonia, all other pulmonary pathogens
Fig. 3 a–c Hazard ratios for ICU death from the adjusted multivariable Cox model: the multivariable Cox model was adjusted for age, sex, and
SOFA score at d0. The hazard ratios are labeled on the x-axis. The horizontal bars are 95% confidence intervals (95% CI), and significant (< 0.05) p
values are indicated with asterisk. a Entire cohort. b Subgroup with low viral load (103–105 HSV copies/mL). c Subgroup with high viral load (>
105 HSV copies/mL)
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detected were adequately treated by antibiotics, and no pa-
tient responded to antibiotic treatment. Additionally, the
therapeutic effect of acyclovir suggests a causative role of
HSV in high load patients. Unfortunately, there are no ran-
domized trials examining acyclovir as a treatment for VAP.
Only one randomized trial exists regarding prophylactic
treatment in patients with acute respiratory distress syn-
drome. Acyclovir reduced HSV detection in viral culture,
but did not reduce mortality [32].
Fourth, the day of material sampling was not standard-
ized, but based on clinical symptoms as judged by clini-
cians and microbiologists. Timing may impact HSV
detection, since HSV load may increase with the length
of mechanical ventilation [33]. Thus, some of our low
viral load patients may have been classified as high load
patients if the PCR had been performed later. However,
they all had clinical signs of pneumonia at the time of
sampling. Moreover, we found no correlation between
time from VAP diagnosis to HSV detection and viral
load (Additional file 1: Figure S1). This suggests that
viral loads may not rapidly increase during several days.
Therefore, we consider this time point as clinically ad-
equate and suggest that a few days of variation in PCR
diagnosis does not significantly alter the results.
Conclusions
Taken together, we showed that acyclovir treatment was
associated with a significantly longer time to death in the
ICU, reduced hazard ratio for ICU death, and improved
circulatory and pulmonary oxygenation function in pa-
tients with VAP not responding to antibiotic treatment
and with high HSV load. We suggest testing all patients
with a diagnosis of antibiotic refractory VAP for HSV rep-
lication in respiratory secretions and considering acyclovir
treatment if more than 105 copies/mL were detected.
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